Okazaki Kentaro, Shingaki Tomotaka, Cai Zhihong, Perez-Nieves Magaly, Fisher Lawrence
Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
Eli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.
Diabetes Ther. 2019 Oct;10(5):1823-1834. doi: 10.1007/s13300-019-0664-9. Epub 2019 Jul 8.
EMOTION was a multinational, noninterventional study surveying current insulin-using adults with type 2 diabetes mellitus (T2D) who were initially reluctant to begin insulin treatment. In this Japanese population subanalysis of EMOTION, we identify the frequency and level of helpfulness of healthcare provider (HCP) actions, and we analyze life events ('actions/events') that assist T2D patients with psychological insulin resistance in the decision to initiate insulin.
Participants were selected from Survey Sampling International and their local partners' market research panels in Japan. Quantitative surveys were administered between December 2016 and August 2017 to patients who met the study criteria. Participants were asked whether 45 actions/events occurred, and to rate the level of helpfulness of the actions/events in contributing to their decision to initiate insulin.
Among the 594 eligible participating adults in the EMOTION study, 99 were from Japan. Despite initial reluctance to begin insulin treatment, 80.8% of the Japanese participants immediately commenced insulin. Practical demonstrations by HCPs on how to use insulin were rated by participants as most helpful. Examples of such practical demonstrations, reported as helping moderately or a lot, were 'HCP walked patient through the process of exactly how to take insulin' (82.8%), 'HCP showed an insulin pen' (79.7%), and 'HCP helped patient to see how simple it was to inject insulin' (79.1%).
This study identifies actions that HCPs can use to assist Japanese patients in deciding whether to initiate insulin. These findings may aid the development of clinical interventions addressing reluctance to begin insulin treatment among Japanese patients with T2D.
Eli Lilly and Company and Boehringer Ingelheim. Plain language summary available for this article.
EMOTION是一项跨国、非干预性研究,旨在调查目前正在使用胰岛素治疗的2型糖尿病(T2D)成年患者,这些患者最初不愿开始胰岛素治疗。在这项针对EMOTION研究的日本人群亚分析中,我们确定了医疗保健提供者(HCP)行为的频率和帮助程度,并分析了有助于T2D患者克服心理性胰岛素抵抗从而决定开始使用胰岛素的生活事件(“行为/事件”)。
参与者从Survey Sampling International及其在日本的当地合作伙伴的市场研究小组中选取。在2016年12月至2017年8月期间,对符合研究标准的患者进行了定量调查。询问参与者45种行为/事件是否发生,并让他们对这些行为/事件在促使其决定开始使用胰岛素方面的帮助程度进行评分。
在EMOTION研究的594名符合条件的成年参与者中,99名来自日本。尽管最初不愿开始胰岛素治疗,但80.8%的日本参与者立即开始使用胰岛素。参与者将HCP关于如何使用胰岛素的实际演示评为最有帮助。据报告有一定帮助或帮助很大的此类实际演示示例包括“HCP向患者详细讲解如何注射胰岛素的过程”(82.8%)、“HCP展示胰岛素笔”(79.7%)以及“HCP帮助患者了解注射胰岛素是多么简单”(79.1%)。
本研究确定了HCP可用于协助日本患者决定是否开始使用胰岛素的行为。这些发现可能有助于开发针对日本T2D患者不愿开始胰岛素治疗问题的临床干预措施。
礼来公司和勃林格殷格翰公司。本文提供了通俗易懂的摘要。